Bio Pharma Dive

MARCH 16, 2022

Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing.

Gene Editing 324

Gene Editing Gene Medicine Development 324

Bio Pharma Dive

JULY 28, 2023

The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.

Gene Editing 246

Gene Editing Gene Sales Research 246

Bio Pharma Dive

MARCH 2, 2023

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

Gene Editing 300

Gene Editing In-Vivo Gene Drugs 300

Bio Pharma Dive

JULY 20, 2022

The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.

Gene Editing 328

Gene Editing Gene Development Drugs 328

Bio Pharma Dive

FEBRUARY 1, 2022

The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance.

Gene Editing 328

Gene Editing Gene Development 328

Bio Pharma Dive

JUNE 26, 2021

Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research.

Gene Editing 363

Gene Editing Gene Medicine Research 363

Rethinking Clinical Trials

JULY 31, 2024

Adrian Hernandez In this Friday’s PCT Grand Rounds, Adrian Hernandez of Duke University will present “Precision Health to Population Health: Opportunities and Challenges for Gene Editing Therapies.” ” The Grand Rounds session will be held on Friday, August 2, 2024, at 1:00 pm eastern. Join the online meeting.

Gene Editing 148

Gene Editing Gene Clinical Trials Clinical Trials 148

Pharmaceutical Technology

APRIL 26, 2024

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

Gene Editing 130

Gene Editing Gene In-Vivo Development 130

Bio Pharma Dive

JULY 23, 2021

The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam.

Gene Editing 337

Gene Editing Gene 337

Bio Pharma Dive

NOVEMBER 2, 2021

The biotech has identified gene editing as a natural fit for the technology it uses to deliver its vaccines and drugs. A deal with Metagenomi, a startup backed by Bayer, will further those ambitions.

Gene Editing 306

Gene Editing Gene Vaccination Vaccine 306

Pharmaceutical Technology

JUNE 29, 2023

Experts warn caution around CRISPR gene editing technology on human embryos as it may have dangerous consequences.

Gene Editing 246

Gene Editing Gene 246

Bio Pharma Dive

FEBRUARY 3, 2022

Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.

Gene Editing 265

Gene Editing Gene Scientist 265

Bio Pharma Dive

JUNE 30, 2021

The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing.

Gene Editing 306

Gene Editing Gene Development Research 306

Worldwide Clinical Trials

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.

Gene Editing 189

Gene Editing Gene Gene Therapy In-Vivo 189

Bio Pharma Dive

JUNE 17, 2021

Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year.

Gene Editing 294

Gene Editing Gene 294

Pharmaceutical Technology

AUGUST 22, 2024

Discover how Verve Therapeutics' new patent for gene editing targeting the PCSK9 gene could revolutionize LDL cholesterol treatment and combat cardiovascular disease.

Gene Editing 100

Gene Editing Gene 100

Pharmaceutical Technology

JANUARY 10, 2023

Asklepios BioPharmaceutical has entered a research partnership and option agreement with ReCode Therapeutics for exploring its single-vector gene-editing platform. The new solution will enable complete gene insertion by delivering the gene-editing tool and DNA as mixed cargo to desired targets in one LNP.

Gene Editing 130

Gene Editing Gene Gene Therapy Genetics 130

Fierce Pharma

FEBRUARY 16, 2024

Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia.

Gene Editing 128

Gene Editing Gene 128

Bio Pharma Dive

MARCH 2, 2022

A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California.

Gene Editing 200

Gene Editing Gene Licensing Licensing 200

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 257

Gene Editing Gene In-Vivo RNA 257

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

NPR Health - Shots

MARCH 6, 2023

The last time this summit convened in 2018, the world was shocked to hear a scientist had created the first gene-edited babies. He was condemned, but gene-editing has continued, with some success. Image credit: Anthony Wallace/AFP via Getty Images)

Gene Editing 133

Gene Editing Gene Scientist 133

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 301

Gene Editing Gene Genetics Medicine 301

Bio Pharma Dive

JANUARY 6, 2024

The Emeryville, California- based gene therapy developer has several preclinical programs in development with Moderna, Ionis and Affini-T.

Gene Editing 208

Gene Editing Gene Gene Therapy Development 208

BioSpace

NOVEMBER 16, 2023

s conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel raises some potential safety concerns with the risk of off-target effects.

Gene Editing 108

Gene Editing Gene Marketing 108

NPR Health - Shots

MARCH 16, 2023

A Mississippi woman's life has been transformed by a treatment for sickle cell disease with the gene-editing technique CRISPR. All her symptoms from a disease once thought incurable have disappeared. Image credit: Orlando Gili for NPR)

Gene Editing 145

Gene Editing Gene 145

pharmaphorum

JANUARY 29, 2021

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Bio Pharma Dive

OCTOBER 3, 2022

Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.

Gene Editing 356

Gene Editing Gene 356

Pharmaceutical Technology

JUNE 15, 2023

Verve Therapeutics and Eli Lilly and Company have entered an exclusive research partnership to advance the former’s preclinical stage in vivo gene editing programme targeting lipoprotein(a) (Lp(a)) to treat atherosclerotic cardiovascular disease (ASCVD).

Gene Editing 130

Gene Editing Gene Gene Therapy In-Vivo 130

Medical Xpress

MAY 1, 2023

Gene-editing therapy aimed at two targets—HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells—can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) shows.

Gene Editing 124

Gene Editing Gene Medicine Drugs 124

Pharmaceutical Technology

NOVEMBER 18, 2024

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.

Gene Editing 130

Gene Editing Gene 130

Bio Pharma Dive

OCTOBER 22, 2024

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Gene Editing 286

Gene Editing In-Vivo Licensing Licensing 286

Fierce Pharma

JANUARY 16, 2024

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.

Gene Editing 119

Gene Editing Gene FDA Approval 119

Bio Pharma Dive

DECEMBER 8, 2023

In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.

Gene Editing 348

Gene Editing Gene 348

Bio Pharma Dive

NOVEMBER 15, 2023

Since halting work on a sickle cell treatment early this year, Graphite Bio has laid off staff, shed assets and, now, agreed to be subsumed via a merger with Lenz Therapeutics.

Gene Editing 268

Gene Editing Gene 268

Bio Pharma Dive

JANUARY 12, 2021

Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking.

Gene Editing 189

Gene Editing Gene Drugs 189

STAT News

FEBRUARY 22, 2023

Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions.

Gene Editing 126

Gene Editing Gene Genetic Disease Research 126